Griffin Asset Management’s Sana Biotechnology SANA Stock Holding History

Griffin Asset Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51K	Hold	14,620	–	–	0.01%	241
2026 Q1	$42.1K	Buy	14,620 +3,000	+26%	+$11.8K	﹤0.01%	224
2025 Q4	$47.3K	Hold	11,620	–	–	0.01%	232
2025 Q3	$41.3K	Buy	+11,620	New	+$42K	﹤0.01%	224

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Griffin Asset Management's SANA Position: Q2 2026 in Review

Griffin Asset Management held its Sana Biotechnology (SANA) position steady in Q2 2026 at 14,620 shares worth $51K. The position accounts for 0.01% of the portfolio, ranked #241.

Griffin Asset Management first reported a position in SANA in Q3 2025 and has held it in 4 quarters since. 212 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Griffin Asset Management held 14,620 shares of Sana Biotechnology worth $51K as of Q2 2026.
Griffin Asset Management left its Sana Biotechnology share count unchanged in Q2 2026.
Sana Biotechnology made up 0.01% of Griffin Asset Management's portfolio in Q2 2026, its #241 holding.
Griffin Asset Management first reported a position in Sana Biotechnology in Q3 2025 and has held it in 4 quarters since.
212 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Griffin Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.